Back
Exelixis 10K Form
Buy
81
EXEL
Exelixis
Last Price:
$44.34
Seasonality Move:
4.88%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-04-30 | 10Q | EXEL/Exelixis Quarterly |
| 2023-11-01 | 10Q | EXEL/Exelixis Quarterly |
| 2023-08-01 | 10Q | EXEL/Exelixis Quarterly |
| 2023-05-09 | 10Q | EXEL/Exelixis Quarterly |
| 2022-11-01 | 10Q | EXEL/Exelixis Quarterly |
| 2022-08-09 | 10Q | EXEL/Exelixis Quarterly |
Receive EXEL News And Ratings
See the #1 stock for the next 7 days that we like better than EXEL
EXEL Financial Statistics
Sales & Book Value
| Annual Sales: | $2.2B |
|---|---|
| Cash Flow: | $189M |
| Price / Cash Flow: | 16.89 |
| Annual Sales: | $7.73 |
| Price / Book: | 5.72 |
Profitability
| EPS (TTM): | 2.20000 |
|---|---|
| Net Income (TTM): | $643.6M |
| Gross Margin: | $2.1B |
| Return on Equity: | 29.53% |
| Return on Assets: | 22.47% |
Exelixis Earnings Forecast
Key Exelixis Financial Ratios
-
The Gross Profit Margin over the past 26 years for EXEL is 96.49%.
-
The Selling, General & Administrative Expenses for EXEL have been equal to 22.69% of Gross Profit Margin.
-
The Research & Development expenses have been 41.98% of Revenue.
-
The Interest Expense is 0.00% of Operating Income.
-
The Net Earning history of EXEL is 24.04% of Total Revenues.
-
Per Share Earnings over the last 27 years have been positive in 17 years.
Exelixis Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | EXEL |
| CUSIP: | 30161Q |
| Website: | exelixis.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 3.5 |
| Quick Ratio: | 3.29 |
Price-to-Earnings
| Trailing P/E Ratio: | 25.39 |
|---|---|
| Forward P/E Ratio: | 14.68 |